DENTSPLY SIRONA (NASDAQ:XRAY) Updates FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.400-1.500 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Up 1.5%

Shares of XRAY traded up $0.17 on Tuesday, hitting $11.37. The company’s stock had a trading volume of 9,474,759 shares, compared to its average volume of 4,473,756. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The firm’s fifty day moving average price is $12.16 and its 200-day moving average price is $12.03. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -3.79, a P/E/G ratio of 1.39 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts expect that DENTSPLY SIRONA will post 1.43 EPS for the current year.

Analyst Ratings Changes

XRAY has been the subject of several research analyst reports. UBS Group decreased their price objective on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Mizuho boosted their price objective on DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their target price for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Citigroup assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price on the stock. Finally, Barrington Research boosted their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.91.

Insider Activity at DENTSPLY SIRONA

In other news, Director James D. Forbes bought 5,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. The trade was a 100.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier acquired 15,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were bought at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the purchase, the director owned 65,000 shares in the company, valued at approximately $809,250. This represents a 30.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 70,000 shares of company stock worth $956,437 in the last 90 days. Company insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Q1 revenue beat and solid adjusted margins: Net sales of $880M topped consensus (~$841.8M) and management reported adjusted gross margin of 50.7% and adjusted EBITDA margin of 14.7%; adjusted EPS was $0.27. These topline and margin signs help explain investor enthusiasm. Q1 Results
• Positive Sentiment: Product differentiation: Launched Smart View‑Detect, the first FDA‑cleared AI diagnostic aid for detecting periapical radiolucencies in CBCT scans (also CE‑marked), which supports longer‑term growth in software/connected solutions. Smart View‑Detect Launch
• Positive Sentiment: U.S. distribution expansion: Enhanced agreement with Atlanta Dental Supply to distribute connected technology solutions starting Aug. 1, broadening go‑to‑market reach for new products and CEREC installations. Atlanta Distribution Agreement
• Positive Sentiment: Capital allocation shift: Management says it is reducing debt, improving liquidity and working capital — moves that can de‑risk the balance sheet and support valuation recovery over time. Capital Allocation
• Neutral Sentiment: FY‑2026 guidance roughly in line with Street: Management set EPS guidance of $1.40–$1.50 (consensus ~ $1.43) and revenue guidance around $3.5–$3.6B — guidance is not a clear beat or miss but leaves little upside relative to expectations. FY2026 Guidance
• Neutral Sentiment: Brokerage sentiment: Consensus analyst rating is around “Hold,” indicating limited near‑term sell/buy conviction from brokers. Analyst Consensus
• Negative Sentiment: Small EPS miss and GAAP loss: Reported adjusted EPS of $0.27 missed the Zacks/consensus ~$0.28 by $0.01, GAAP net loss per share was $(0.05), and EPS is down from $0.43 a year ago — near‑term profitability concerns remain. Earnings Miss
• Negative Sentiment: Near‑term headwinds: Analysts flagged U.S. demand softness, tariff pressures and transformation costs that could weigh on margins and cash flow in the near term. Headwinds Preview

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently made changes to their positions in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Goldman Sachs Group Inc. raised its stake in DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the period. Empowered Funds LLC raised its stake in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth raised its stake in DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares during the period. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.